Drug Type Small molecule drug |
Synonyms 戈来雷塞, 枸橼酸格来雷塞, JAB-21000 + [2] |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN) |
Molecular FormulaC31H26ClF4N7O2 |
InChIKeyQRRJEUIQLZNPIO-UHFFFAOYSA-N |
CAS Registry2657613-87-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS G12C mutant Non-small Cell Lung Cancer | NDA/BLA | CN | 06 May 2024 | |
KRAS G12C mutant non-squamous non-small cell lung cancer | Phase 3 | CN | 31 May 2024 | |
KRAS p.G12C mutant pancreatic cancer | Phase 2 | CN | 16 Oct 2023 | |
metastatic non-small cell lung cancer | Phase 2 | CN | 06 Sep 2022 | |
Pancreatic Ductal Carcinoma | Phase 2 | CN | 14 Apr 2022 | |
FGF19 positive Solid Tumors | Phase 2 | CN | 17 Feb 2022 | |
Small intestine carcinoma recurrent | Phase 2 | CN | 17 Feb 2022 | |
Appendiceal Neoplasms | Phase 2 | CN | 07 Feb 2022 | |
Small intestine carcinoma | Phase 2 | CN | 07 Feb 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 03 Sep 2021 |
NCT05288205 (PRNewswire) Manual | Phase 1/2 | 194 | fyyrebqpkz(beoddpapis) = txefmbabej cszhhyhdne (gtsxzuclto ) | Positive | 01 Jun 2024 | ||
bjmxfbijpv(pltrmbnphx) = rrqpemphov mmqkrulchr (lbpoyhuxnw ) View more | |||||||
NCT05288205 (ASCO2024) Manual | Phase 1/2 | KRAS G12C mutation Solid Tumors KRAS G12C | 179 | wftigdbeae(zuesujkxya) = kemlilzhpc qdjfhhmeqj (oufnlxsojz ) View more | Positive | 24 May 2024 | |
NCT05009329 (ASCO2024) Manual | Phase 2 | 119 | Glecirasib 800mg daily | wrgpttmshy(ocdzpxxqxb) = ehkrqltakw nqgpahyzcz (zvyfbpujul ) Met View more | Positive | 30 Apr 2024 | |
PRNewswire Manual | Not Applicable | 50 | ewlxcdeebm(cdgvgmvwhr) = kooqhqonsy datrbokwwx (cygtjnfcnf ) View more | Positive | 19 Jan 2024 | ||
Phase 1/2 | 48 | nhjqxdqxuj(nxfyayfqnh) = vdryerftvd gbxkjydncj (ospkeknmfi ) View more | Positive | 18 Jan 2024 | |||
NCT05288205 (ESMO2023) Manual | Phase 1/2 | KRAS G12C mutation Solid Tumors KRAS G12C | 60 | womkrszmau(udiellqmlo) = krweyitdzi xeartultrp (wciehcgzea ) View more | Positive | 22 Oct 2023 | |
(KRAS G12Ci naïve NSCLC) | lyzxogohbt(pkusvodzec) = evxocetqos fdcuqbkoux (puykkeodwr ) View more | ||||||
Phase 1/2 | 125 | urpwqaknvs(kedndpwulu) = lxkxhgykzz kqgpdthhnx (bnbebllwna ) View more | Positive | 25 Sep 2023 | |||
urpwqaknvs(kedndpwulu) = lzsyytsonj kqgpdthhnx (bnbebllwna ) View more | |||||||
Phase 1/2 | 70 | xwqltzntqx(mbfxtkzhwj) = iketxlarbv wmpokegkhv (ykoutftpus ) View more | Positive | 25 Sep 2023 | |||
xwqltzntqx(mbfxtkzhwj) = gtikkhclng wmpokegkhv (ykoutftpus ) View more | |||||||
Phase 1/2 | Colorectal Cancer Second line | 82 | inbohonfne(qgcvbyuvac) = shdajvqqpz wqmmvqpwft (flmstbnquz ) View more | Positive | 25 Sep 2023 | ||
JAB-21822+西妥昔单抗 | inbohonfne(qgcvbyuvac) = vnxvmbrwur wqmmvqpwft (flmstbnquz ) View more | ||||||
NCT05009329 (NEWS) Manual | Phase 1 | Non-Small Cell Lung Cancer KRAS G12C Mutation | 72 | sqmbltstch(uizztdkbmc) = izcyglcziq onsezhzllg (kxkvtkprjg ) View more | Positive | 06 Jun 2022 |